Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32688514 | 0.78 | HPGD (0.40) | HPGDLMNASMN1; SMN2EPHX2POLB | |
| SCHEMBL32688344 | 0.78 | HPGD (0.43) | HPGDLMNASMN1; SMN2EPHX2POLB | |
| SCHEMBL32688630 | 0.75 | ALDH1A1 (0.42) | HPGDLMNASMN1; SMN2EPHX2POLB | |
| SCHEMBL32689202 | 0.72 | HPGD (0.46) | HPGDLMNASMN1; SMN2EPHX2POLB | |
| SCHEMBL32688351 | 0.70 | HPGD (0.49) | HPGDLMNASMN1; SMN2EPHX2POLB | |
| SCHEMBL32688772 | 0.70 | HPGD (0.37) | HPGDLMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL32688505 | 0.69 | HPGD (0.47) | HPGDLMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL32689083 | 0.69 | HPGD (0.44) | HPGDLMNASMN1; SMN2EPHX2POLB | |
| SCHEMBL32688980 | 0.69 | HPGD (0.41) | HPGDLMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL16468784 | 0.68 | HPGD (0.39) | HPGDLMNASMN1; SMN2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078079-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NORBORNANE AND NORBORNENE DERIVATIVES | OSMO LABS PBC (US) | 2026-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078079-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NORBORNANE AND NORBORNENE DERIVATIVES | CBR1, CBR3, TAS2R1 | HPGD 709/4885LMNA 2153/4885SMN1; SMN2 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.